Comparative safety of prescribed Esketamine and ketamine in relation to renal and urinary disorders: A pharmacovigilance perspective.
Progress in neuro-psychopharmacology & biological psychiatry January 10, 2025 S Chiappini, A Guirguis, N Schifano et al. 12 citations
Intranasal esketamine, the S-enantiomer of ketamine, is approved with oral antidepressants for treatment-resistant depression and offers rapid absorption. Analysis of FDA Adverse Events Reporting System data up to May 2024 compared urological safety profiles of esketamine, ketamine, and several other antidepressants and antipsychotics. Risperidone had the highest total adverse drug reactions (107,418) and serious cases (71,515), including acute kidney injury and urinary incontinence. Esketamine and ketamine were associated with lower urinary tract symptoms and nephrolithiasis. Disproportionality analysis showed ketamine had higher odds of renal and urinary disorders, while esketamine had lower or comparable odds, suggesting a relatively favorable tolerability profile for esketamine.